Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors

NCT00474760 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00474760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00474760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
October 31, 2012
Enrollment
65 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, ewing's